Author: veridonglobal.dev@gmail.com

ToxiProofAI is redefining how drug discovery teams predict, monitor, and mitigate safety risks across the drug development lifecycle.

Built specifically for complex biological therapies, the platform integrates multi-omics, real-world toxicology data, and advanced machine learning to deliver early, actionable insight into potential immune-related adverse events (irAEs) and off-target liabilities. By detecting subtle biological patterns that conventional tools often miss, ToxiProofAI helps researchers design safer modalities, prioritize the right candidates, and avoid costly late-stage surprises.

During clinical development, ToxiProofAI supports patient selection, dose optimization, and early detection of toxicity signals, ultimately de-risking trials and accelerating time to meaningful clinical readouts. By transforming safety assessment from a reactive process into a predictive, data-driven capability, ToxiProofAI empowers organizations to advance innovative drugs, such as IO therapies with greater confidence, speed, and precision.

1. In your view, what are the most significant recent trends and advancements in immuno-oncology and biomarker science — particularly those that are reshaping how we discover, develop, and evaluate cancer therapies?

Bright red-shifted and colour-shifting near-infrared bioluminescence systems have been developed which are as versatile as standard the firefly bioluminescence system but can light two types of cell or gene pathway simultaneously in vivo, e.g. in cancer (like T-cell CAR research), stem-cell research, mRNA technologies, gene therapy and countless other biomedical fields, non-invasively and longitudinally with greater quantifiability and better imaging rendering than ever before.

2️. Without giving too much away, what key takeaways should our audience anticipate from your presentation — and how might these insights contribute to accelerating clinical impact in IO/ biomarker development?

We have developed new brighter dual-colour near infrared enzymes that utilise infraluciferin to mark two types of cell or gene that can be imaged simultaneously in vitro and animals using standared imaging equipment. The output of our new enzymes equals the light output of bright analog aminoluciferin and we are developing even brighter variants, and those that allow triple parameter bioluminescence imaging in vitro and in vivo.

As the pharmaceutical industry propels forward with transformative therapies and next-generation drug manufacturing, safety, precision, and innovation have never been more critical. This is why we’re excited to share that FPS Pharma is proud to be the Gold Sponsor at the upcoming Veridon Global event  2nd Annual EuroPotent 360 Summit a premier forum where industry leaders, innovators, and change-makers converge to shape the future of healthcare and pharmaceutical technology.

At the heart of FPS Pharma’s mission lies an unwavering commitment to enabling safer and more efficient pharmaceutical processes — especially in handling high-potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs). With cutting-edge containment isolators, advanced compliance tools, and next-level engineering solutions, FPS Pharma is empowering manufacturers to operate at new levels of excellence.

Why FPS Pharma Leads in High-Containment and Isolation Technology

Pharmaceutical manufacturing increasingly relies on ultra-precise control over environments where potent compounds are handled. FPS Pharma’s custom containment isolators are engineered to meet this demand, safeguarding both operators and product integrity by creating controlled, sealed environments tailored to customer needs. These isolators are vital for HPAPI and ADC processing — providing top-tier containment (up to Occupational Exposure Band (OEB) levels like OEB 7) and compliance with global regulatory standards such as FDA, EMA, OSHA, and cGMP.

Unlike standard cleanroom systems, containment isolators operate under negative pressure to prevent hazardous compounds from escaping, while also offering ergonomic, integrated designs for ease of operation and maintenance. Whether for sampling, formulation, filtration, or packaging, these systems ensure a safe and seamless interface between complex processes and stringent safety requirements.

Keeping Pace with Ultra-Potent API Manufacturing

As pharmaceutical innovation accelerates, the industry is now dealing with compounds of extraordinary potency — where exposure limits are measured in single-digit nanograms per cubic meter. To meet this challenge, FPS Pharma has pioneered containment systems like OEB 7 isolators, representing the new frontier in ultra-potent API containment. These systems go beyond conventional frameworks to handle the most hazardous materials safely, offering customized solutions that integrate advanced features such as closed transfer systems, automated cleaning (CIP/WIP/SIP), real-time monitoring, and robotics.

These isolators act not only as equipment but as strategic enablers, allowing manufacturers to explore new chemistries and scale operations with confidence — reinforcing FPS Pharma’s role as a trusted partner for pharmaceutical companies and contract development and manufacturing organizations (CDMOs) worldwide.

Ensuring Compliance and Operational Efficiency

In addition to containment systems, FPS Pharma offers innovative tools like GloveXpert, a wireless glove leak tester designed specifically for isolators and Restricted Access Barrier Systems (RABS). This advanced system performs rapid, reliable integrity testing — critical for regulatory compliance (including EU GMP Annex 1 and FDA standards) — while dramatically reducing inspection time and risk of contamination.

With features like pressure decay testing, RFID traceability, integrated Wi-Fi, and compatibility with digital control infrastructure, GloveXpert exemplifies how technology and design converge to elevate safety, efficiency, and confidence in pharmaceutical processing operations.

Looking Ahead: FPS Pharma at Veridon Global

As Veridon Global brings together leaders from across healthcare, life sciences, and technology, FPS Pharma’s role as Gold Sponsor underscores its strategic vision: to help the industry innovate boldly while operating within the highest standards of safety and compliance. From high-containment isolators to next-generation API manufacturing solutions, FPS Pharma continues to push boundaries and redefine what’s possible in pharmaceutical production.

We look forward to meaningful conversations at 2nd Annual EuroPotent 360 Summit — connecting, learning, and co-creating safer, smarter pharmaceutical futures. Stay tuned for more insights and highlights from the event!

Article shared with permission from FPS.

The integration of digital health technologies is dramatically transforming how real-world evidence (RWE) is collected, analyzed, and applied across the healthcare and life sciences ecosystem. Once a slow, expensive, and fragmented process, RWE generation is now being streamlined and enhanced by innovations such as artificial intelligence (AI) and natural language processing (NLP) — delivering timely, high-quality insights that fuel smarter decisions in drug development, clinical research, and healthcare delivery.

Accelerating and Optimizing RWE Through Technology

Traditionally, RWE collection involved manual data gathering, cumbersome patient tracking, and reliance on outdated data sources. This approach often led to delayed results, increased costs, and insights that didn’t meet the rigorous standards required for evidence-based decision-making.

Today, digital health tools enable healthcare stakeholders to automate and scale this process. AI and NLP, for example, allow for real-time data extraction and sophisticated analysis of both structured and unstructured health data — unlocking more comprehensive patient insights. These technologies help generate high-quality RWE that is not only timely but also more relevant and actionable than ever before.

As Esther, a thought leader in digital health, highlights:

“Digital health technologies not only accelerate but also significantly optimize real-world evidence generation and utilization.”

The Role of AI and Machine Learning in Evidence Generation

AI and machine learning are rapidly becoming cornerstones of modern evidence generation. These technologies can bridge the gaps in fragmented datasets, drawing from diverse data sources like electronic health records (EHRs), patient registries, and even wearable devices. AI helps identify relevant study populations, predict outcomes, and generate real-time insights that support critical decision-making across the clinical and commercial lifecycle.

According to Lisa, a digital innovation expert:

“AI can enrich and curate incomplete datasets to provide optimal insights used throughout the development timeline.”

From improving patient stratification in trials to optimizing treatment pathways, the impact of AI on RWE cannot be overstated. Its ability to analyze vast volumes of data quickly and accurately is changing the way researchers and healthcare providers understand the patient journey.

Tackling Data Quality and Interoperability Challenges

One of the biggest challenges in RWE generation has historically been data quality and interoperability. While data availability has increased, the reliability, completeness, and usability of that data remain concerns.

Natural Language Processing (NLP) is emerging as a breakthrough solution. By converting unstructured text — such as physician notes or clinical summaries — into structured, usable data, NLP enriches real-world datasets with previously inaccessible insights. This leads to more holistic patient profiles and more accurate research outcomes.

Lisa explains:

“These challenges can be efficiently addressed through real-time data extraction and curation using AI. NLP can enrich real-world datasets by analyzing and converting unstructured to structured data points.”

Embracing Innovation for a Smarter Healthcare Future

The integration of digital technologies into RWE generation isn’t just a technical upgrade — it’s a paradigm shift. It empowers both life sciences companies and healthcare institutions to unlock the full potential of real-world data (RWD), enhancing drug development, clinical trial design, patient recruitment, and post-market surveillance.

Esther summarizes the key message:

“Healthcare innovation is driven by enriched, dynamic real-world data enabled by cutting-edge technologies and global collaboration.”

Key Takeaway

Embracing AI, NLP, and digital health tools transforms how we collect, curate, and utilize real-world evidence. These technologies elevate data quality, reduce inefficiencies, and ultimately support more personalized, effective healthcare solutions. As the healthcare industry moves toward data-driven innovation, the ability to harness high-quality RWE will be a defining factor in shaping the future of patient care and therapeutic success.

Register for our upcoming

• EVIDENCE 360: RWE, Pricing & Reimbursement Summit Europe
• EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA